会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Method of biomedical signal analysis including improved automatic segmentation
    • 生物医学信号分析方法包括改进的自动分割
    • US08332017B2
    • 2012-12-11
    • US12517127
    • 2007-11-30
    • Lionel TarassenkoAlan PattersonIain Guy Strachan
    • Lionel TarassenkoAlan PattersonIain Guy Strachan
    • A61B5/04
    • A61B5/0452A61B5/7203A61B5/7267
    • A method of analysing biomedical signals, for example electrocardiograms, by using a Hidden Markov Model for subsections of the signal. In the case of an electrocardiogram two Hidden Markov Models are used to detect respectively the start and end of the QT interval. The relationship between the QT interval and heart rate can be computed and a contemporaneous value for the slope of this relationship can be obtained by calculating the QT/RR relationship for all of the beats in a sliding time window based on the current beat. Portions of electrocardiograms taken on different days can efficiently and accurately be compared by selecting time windows of the ECGs at the same time of day, and looking for similar beats in those time windows.
    • 通过使用隐马尔科夫模型来分析生物医学信号(例如心电图)来分析信号的子部分的方法。 在心电图的情况下,使用两个隐马尔可夫模型分别检测QT间隔的开始和结束。 可以计算QT间隔和心率之间的关系,并且可以通过基于当前节拍计算滑动时间窗口中的所有节拍的QT / RR关系来获得该关系的斜率的同期值。 通过在一天的同一时间选择ECG的时间窗口,并在这些时间窗口中寻找类似的节拍,可以有效和准确地比较在不同日期拍摄的部分心电图。
    • 3. 发明授权
    • Biomedical signal morphology analysis method
    • 生物医学信号形态分析方法
    • US08290575B2
    • 2012-10-16
    • US12517136
    • 2007-11-30
    • Lionel TarassenkoAlan PattersonIain Guy Strachan
    • Lionel TarassenkoAlan PattersonIain Guy Strachan
    • A61B5/04
    • A61B5/0452A61B5/0468A61B5/0476A61B5/1455A61B5/7267
    • A way of quantifying the shape of an ECG waveform is disclosed by detecting the JT segment using two Hidden Markov Models and calculating the analytic signal of the JT segment. Parameters calculated from the analytic signal are used as shape descriptors for the JT segment. The shape descriptors may be displayed in a dimensionality-reduced mapping. Templates representing characteristic shapes can be produced by finding cluster centers in the shape descriptor space, and the novelty of new waveforms can be quantified by comparing the position in shape descriptor space of new shape descriptors to a predefined normal training set or to previously encountered waveforms. Novel shape descriptors can be used to retrieve the corresponding waveforms, and templates of such novel shapes can be created by averaging such waveforms, using dynamic time warping to allow for variations in heart rate. The templates can be manually segmented and the manual segmentation propagated back into other waveforms having similar shape descriptors.
    • 通过使用两个隐马尔可夫模型检测JT段并计算JT段的分析信号来公开量化ECG波形形状的方法。 从分析信号计算的参数用作JT段的形状描述符。 形状描述符可以被显示在维度降低的映射中。 可以通过在形状描述符空间中发现聚类中心来产生表征特征形状的模板,并且可以通过将新形状描述符的形状描述符空间中的位置与预定义的正常训练集或先前遇到的波形进行比较来量化新波形的新颖性。 可以使用新颖的形状描述符来检索相应的波形,并且可以通过使用动态时间扭曲来平均这样的波形来创建这种新形状的模板,以允许心率的变化。 模板可以手动分割,手动分割传播回具有类似形状描述符的其他波形。
    • 4. 发明申请
    • BIOMEDICAL SIGNAL MORPHOLOGY ANALYSIS METHOD
    • 生物医学信号分析方法
    • US20100049069A1
    • 2010-02-25
    • US12517136
    • 2007-11-30
    • Lionel TarassenkoAlan PattersonGuy Strachan
    • Lionel TarassenkoAlan PattersonGuy Strachan
    • A61B5/0452A61B5/0402
    • A61B5/0452A61B5/0468A61B5/0476A61B5/1455A61B5/7267
    • A way of quantifying the shape of an ECG waveform is disclosed by detecting the JT segment using two Hidden Markov Models and calculating the analytic signal of the JT segment. Parameters calculated from the analytic signal are used as shape descriptors for the JT segment. The shape descriptors may be displayed in a dimensionality-reduced mapping. Templates representing characteristic shapes can be produced by finding cluster centres in the shape descriptor space, and the novelty of new waveforms can be quantified by comparing the position in shape descriptor space of new shape descriptors to a predefined normal training set or to previously encountered waveforms. Novel shape descriptors can be used to retrieve the corresponding waveforms, and templates of such novel shapes can be created by averaging such waveforms, using dynamic time warping to allow for variations in heart rate. The templates can be manually segmented and the manual segmentation propagated back into other waveforms having similar shape descriptors.
    • 通过使用两个隐马尔可夫模型检测JT段并计算JT段的分析信号来公开量化ECG波形形状的方法。 从分析信号计算的参数用作JT段的形状描述符。 形状描述符可以被显示在维度降低的映射中。 可以通过在形状描述符空间中发现聚类中心来产生表征特征形状的模板,并且可以通过将新形状描述符的形状描述符空间中的位置与预定义的正常训练集或先前遇到的波形进行比较来量化新波形的新颖性。 可以使用新颖的形状描述符来检索相应的波形,并且可以通过使用动态时间扭曲来平均这样的波形来创建这种新形状的模板,以允许心率的变化。 模板可以手动分割,手动分割传播回具有类似形状描述符的其他波形。
    • 6. 发明授权
    • Long-acting oxytetracycline composition
    • 长效土霉素组成
    • US06310053B1
    • 2001-10-30
    • US09617795
    • 2000-07-17
    • Alan PattersonDrew Holmes
    • Alan PattersonDrew Holmes
    • A61K3165
    • A61K47/02A61K9/0019A61K9/08A61K31/65A61K47/10A61K47/22
    • An injectable composition is described having a higher residual effect with reduced detrimental effects such as pain at injection site, swelling, tissue irritancy or necrosis. The composition contains as active principle a tetracycline compound, either as the free base or a salt thereof with a physiologically acceptable acid, complexed with a substantially equimolar amount of a magnesium compound, and is solubilized in a water miscible solvent system comprising glycerol formal in a an amount of about 40 (v/v); with from about 1% to about 20% (v/v) polyethylene glycol and optionally containing a pH modifier in an amount sufficient to maintain a physiologically acceptable pH. In addition, the composition may further comprise a thickener, such as polyvinyl in an amount of about 10% (w/v). The balance of the composition comprises water.
    • 描述了具有较高残留效应并具有降低的有害作用如注射部位疼痛,肿胀,组织刺激或坏死的可注射组合物。 该组合物作为活性成分含有四环素化合物,其作为游离碱或其与生理上可接受的酸的盐,与基本上等摩尔量的镁化合物络合,并且溶解在包含甘油缩合物的水混溶性溶剂体系中 约为40(v / v); 与约1%至约20%(v / v)的聚乙二醇,并且任选地含有足以维持生理上可接受的pH的量的pH调节剂。 此外,组合物还可以包含约10%(w / v)的增稠剂,例如聚乙烯。 组合物的余量包括水。
    • 7. 发明授权
    • Long-acting oxytetracycline composition
    • 长效土霉素组成
    • US6110905A
    • 2000-08-29
    • US159680
    • 1998-09-24
    • Alan PattersonDrew Holmes
    • Alan PattersonDrew Holmes
    • A61K9/08A61K31/65A61K47/02A61K47/10A61K47/22
    • A61K9/08A61K31/65A61K47/02A61K47/10A61K47/22A61K9/0019
    • An injectable composition of higher residual effect with reduced detrimental effects such as pain at injection site, swelling, tissue irritancy or necrosis and containing as active principle a tetracycline compound, either as the free base or a salt thereof with a physiologically acceptable acid, complexed with a substantially equimolar amount of a magnesium compound, is solubilized in a water miscible solvent system comprising, either (i) a) glycerol formal in an amount of from about 10 to 50% v/v; with b) polyethylene glycol in an amount of from about 1 to 15% v/v; or (ii) from about 25 to about 75% v/v of N-methylpyrrolidone, the composition optionally containing a pH modifier in an amount sufficient to maintain a physiochemically acceptable pH, the balance being made up with water q.s.
    • 具有较高残留效应的可注射组合物,其具有降低的有害作用,例如注射部位疼痛,肿胀,组织刺激或坏死,并且作为活性成分含有四环素类化合物,作为游离碱或其与生理学上可接受的酸的盐,与 基本上等摩尔量的镁化合物溶解在水混溶性体系中,其包含(i)a)约10至50%v / v的量的甘油缩甲醛; 其中b)约1至15%v / v的量的聚乙二醇; 或(ii)约25至约75%v / v的N-甲基吡咯烷酮,所述组合物任选地含有一定量的pH调节剂,其量足以保持生理学上可接受的pH,余量由水补足。